Oxaliplatin News and Research

RSS
Duloxetine drug alleviates pain from chemotherapy

Duloxetine drug alleviates pain from chemotherapy

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Regeneron fourth quarter total revenues increase to $415 million

Regeneron fourth quarter total revenues increase to $415 million

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Oxaliplatin and bevacizumab disappoint for rectal cancer

Oxaliplatin and bevacizumab disappoint for rectal cancer

Personalized rectal cancer therapy shows promise

Personalized rectal cancer therapy shows promise

Bevacizumab ruled out for stage III colorectal cancer

Bevacizumab ruled out for stage III colorectal cancer

FoXTROT results: preoperative chemo could become new standard

FoXTROT results: preoperative chemo could become new standard

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

Usefulness of liver biopsy for CALI preoperative assessment questioned

Usefulness of liver biopsy for CALI preoperative assessment questioned

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

Aeterna Zentaris announces results from perifosine Phase 3 trial on colorectal cancer

Aeterna Zentaris announces results from perifosine Phase 3 trial on colorectal cancer

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

SLU investigator aims to reduce chemotherapy-induced peripheral neuropathy

SLU investigator aims to reduce chemotherapy-induced peripheral neuropathy

Cancer cell communication signals may contain pieces of RNA

Cancer cell communication signals may contain pieces of RNA

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Strategies to minimize side effects of oxaliplatin in metastatic colon cancer

Strategies to minimize side effects of oxaliplatin in metastatic colon cancer